Interestingly, adriamycin combined with mulandine can prevent breast cancer by inducing the expression of autophagy markers beclin-1 and LC3-II in breast carcinoma cells, reducing the expression level of p62, and inhibiting the PI3K/AKT/mTOR signaling pathway, suggesting that autophagy may be a form of cancer cell death induced by anticancer drugs 24. Here, MTOR is linked to breast carcinoma.